| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 143.9 | 99.2 |
| Net income | 8.8 | 7.4 |
| EPS (diluted, $ a share) | $0.06 | $0.06 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | +18.8% |
|---|---|
| Revenue, year on year | +45.1% |
| Operating margin | 6.6% |
10-Q filed with the SEC, NASDAQ: ARQT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Arcutis Biotherapeutics, Inc.: key numbers
- Share price
- $27.33Close, Nov 17
- Market cap
- $3.46B
- Shares outstanding
- 126.46MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Arcutis Biotherapeutics, Inc.
All →Arcutis Biotherapeutics EVP, CLO Masaru Matsuda Sells $1.41M of Stock
Masaru Matsuda, EVP, CLO, sold 41,219 shares of Arcutis Biotherapeutics, Inc. at $31.86 to $34.32 a share (average $34.24) in 2 transactions, worth $1.41M in total between Nov 2, 2026 and Nov 4, 2026. Shares held after the trade: 111,289 (-26.4%).
- Value
- $1.41M
- Shares
- 41,219
- Average price
- $34.24
- Role
- EVP, CLO
- Holding change
- -26.4%
- Trade date
- Nov 2, 2026 to Nov 4, 2026
Arcutis Biotherapeutics EVP, CMO Patrick Burnett Sells $30K of Stock
Patrick Burnett, EVP, CMO, sold 943 shares of Arcutis Biotherapeutics, Inc. at $31.86 a share, worth $30K in total on Nov 2, 2026. Shares held after the trade: 116,649 (-0.8%).
- Value
- $30K
- Shares
- 943
- Price
- $31.86
- Role
- EVP, CMO
- Holding change
- -0.8%
- Trade date
- Nov 2, 2026
Arcutis Biotherapeutics Insider Todd Watanabe Sells $139K of Stock
Todd Watanabe sold 4,377 shares of Arcutis Biotherapeutics, Inc. at $31.86 a share, worth $139K in total on Nov 2, 2026. Shares held after the trade: 712,826 (-0.6%).
- Value
- $139K
- Shares
- 4,377
- Price
- $31.86
- Holding change
- -0.6%
- Trade date
- Nov 2, 2026
Arcutis Biotherapeutics Financial Results
Arcutis Biotherapeutics reported Q3 2026 net product revenues of $143.9 million, a 45% year-over-year increase driven by strong demand for its ZORYVE portfolio. The company maintained positive operating cash flow of $18.9 million and raised its full-year 2026 net product sales guidance to a range of $535 million to $545 million.
- Term
- quarter ended September 30, 2026
“Yet another strong quarter of performance reflects the consistent execution of our corporate strategy and further strengthens our financial position. ZORYVE continues to lead the branded non-steroidal topical segment driven by its efficacy and tolerability across multiple inflammatory skin conditions and patient populations.”
Frank Watanabe, president and chief executive officer
Arcutis Biotherapeutics Leadership Change
Arcutis Biotherapeutics appointed Dr. Robert Scott to its Board of Directors and the Nominating and Corporate Governance Committee, effective October 23, 2026. Dr. Scott, a former Chief Medical Officer at AbbVie and Amgen, joins as a Class II director with a term expiring in 2028. As part of his appointment, he received an initial stock option award for 20,507 shares of common stock.
Arcutis Biotherapeutics Insider Howard G. Welgus Sells $127K of Stock
Howard G. Welgus sold 4,728 shares of Arcutis Biotherapeutics, Inc. at $26.93 a share, worth $127K in total on Oct 15, 2026. Shares held after the trade: 35,207 (-11.8%).
- Value
- $127K
- Shares
- 4,728
- Price
- $26.93
- Holding change
- -11.8%
- Trade date
- Oct 15, 2026